P
Pablo Tamayo
Researcher at University of California, San Diego
Publications - 185
Citations - 117545
Pablo Tamayo is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Cancer & Gene. The author has an hindex of 72, co-authored 177 publications receiving 97318 citations. Previous affiliations of Pablo Tamayo include University of California, Berkeley & Harvard University.
Papers
More filters
Journal ArticleDOI
KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine
Michelle Stewart,Pablo Tamayo,Andrew J. Wilson,Stephanie Wang,Yun Min Chang,Jong Wook Kim,Dineo Khabele,Alykhan F. Shamji,Stuart L. Schreiber +8 more
TL;DR: The results define the RAS/MEK/DNMT1 pathway as a determinant of sensitivity to DNA methyltransferase inhibition, specifically implicating KRAS status as a biomarker of drug response in ovarian cancer.
Journal ArticleDOI
Kataegis Expression Signature in Breast Cancer Is Associated with Late Onset, Better Prognosis, and Higher HER2 Levels
TL;DR: It is shown that kataegis loci are enriched in high-grade, HER2(+) tumors in patients diagnosed with breast cancer at an older age and who have a later age at death.
Journal ArticleDOI
GeneCruiser: a web service for the annotation of microarray data
TL;DR: GeneCruiser is a web service allowing users to annotate their genomic data by mapping microarray feature identifiers to gene identifiers from databases, such as UniGene, while providing links to web resources,such as the UCSC Genome Browser.
Journal ArticleDOI
Identification of novel prostate cancer drivers using RegNetDriver: a framework for integration of genetic and epigenetic alterations with tissue-specific regulatory network
Priyanka Dhingra,Alexander Martinez-Fundichely,Adeline Berger,Franklin W. Huang,Franklin W. Huang,Andre Neil Forbes,Eric Minwei Liu,Deli Liu,Andrea Sboner,Andrea Sboner,Pablo Tamayo,Pablo Tamayo,David S. Rickman,David S. Rickman,Mark A. Rubin,Mark A. Rubin,Ekta Khurana +16 more
TL;DR: A novel computational method is reported to identify tumorigenic drivers using the combined effects of coding and non-coding single nucleotide variants, structural variants, and DNA methylation changes in the DNase I hypersensitivity based regulatory network.
Journal ArticleDOI
Functional precision medicine identifies new therapeutic candidates for medulloblastoma
Jessica M. Rusert,Edwin F. Juarez,Sebastian Brabetz,James Jensen,Alexandra Garancher,Lianne Q. Chau,Silvia K. Tacheva-Grigorova,Sameerah Wahab,Yoko T. Udaka,Darren Finlay,Huriye Seker-Cin,Brendan Reardon,Brendan Reardon,Susanne Gröbner,Jonathan Serrano,Jonas Ecker,Jonas Ecker,Lin Qi,Mari Kogiso,Yuchen Du,Yuchen Du,Patricia Baxter,Patricia Baxter,Jacob J. Henderson,Michael E. Berens,Kristiina Vuori,Till Milde,Till Milde,Yoon Jae Cho,Xiao-Nan Li,Xiao-Nan Li,James M. Olson,Iris Reyes,Matija Snuderl,Terence C. Wong,David Dimmock,Shareef Nahas,Denise M. Malicki,Denise M. Malicki,John R. Crawford,John R. Crawford,Michael J. Levy,Michael J. Levy,Eliezer M. Van Allen,Eliezer M. Van Allen,Stefan M. Pfister,Stefan M. Pfister,Pablo Tamayo,Marcel Kool,Jill P. Mesirov,Robert J. Wechsler-Reya,Robert J. Wechsler-Reya,Robert J. Wechsler-Reya +52 more
TL;DR: Functional analysis of tumor cells was successfully used in a clinical setting to identify more treatment options than sequencing alone and suggest that it should be possible to move away from a one-size-fits-all approach and begin to treat each patient with therapies that are effective against their specific tumor.